Toll-like Receptor (TLR)

Toll-like Receptor (TLR) Related Products (264):

By Effects:	Controls (2) Inhibitors (78) Ligand (1) Agonists (74) Antagonists (20) Activators (27) Modulator (1) Chemical (1) Inducer (1)

Cat. No.	Product Name	Effect	Purity

HY-153808

Complete Freund's adjuvant (CFA)
Complete Freund's adjuvant (CFA) is an immunoadjuvant emulsified with antigen by its discoverer Jules T. Freund to enhance an animal's immune response to an antigen. Complete Freund's adjuvant (CFA) is also an inducer of the Th1 immune response and a ligand of TLRs. Complete Freund's adjuvant (CFA) contains heat-killed inactive tuberculosis bacilli and consists of a paraffin oil-in-water emulsion. Complete Freund's adjuvant (CFA) stimulates a strong and durable immune response and can be used to induce persistent inflammatory pain models in mice, experimental autoimmune myocarditis (EAM) models, and more. Incomplete Freund's adjuvant (IFA) (HY-153808A) is another type of Freund's Adjuvant that stimulates a weaker immune response.

HY-129522

Sulfo-ara-F-NMN	Activator	99.36%
Sulfo-ara-F-NMN (CZ-48) is a mimetic of nicotinamide mononucleotide (NMN). Sulfo-ara-F-NMN acts selectively, activating SARM1 but inhibiting CD38 (IC₅₀ around 10 μM). Sulfo-ara-F-NMN induces intracellular cyclic ADP-ribose (cADPR) production.

HY-P9930

Evolocumab	Inhibitor	98.40%
Evolocumab (AMG 145) is a human monoclonal antibody that inhibits PCSK9. Evolocumab is used in the study of hypercholesterolemia and atherosclerotic cardiovascular disease. Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. Evolocumab has antioxidant and cytoprotective activities against H₂O₂-induced oxidative damage to endothelial cells. Evolocumab may also negatively regulate activation of the TLR-4/NF-κB signaling pathway to prevent inflammation.

HY-149652

IRF5-IN-1	Inhibitor	99.91%
IRF5-IN-1 (compound C5) is an IRF5 pathway-specific inhibitor. IRF5-IN-1 significantly reduces IRF5 nuclear translocation without affecting the activation of NF-κB p65. IRF5-IN-1 acts through SLC15A4 to selectively inhibit TLR7/8-induced IRF5 responses in cells.

HY-131166

Curdlan	Activator	≥98.0%
Curdlan is a polysaccharide found in bacteria, consisting of a glucose homopolymer with β-1,3-glycosidic linkages. Curdlan can be recognized by Dectin-1 (a C-type lectin receptor), inducing immune responses in tissue mast cells and enhancing dendritic cell effects in tumor immunity. Curdlan holds potential for research in cancer and immune-inflammatory diseases.

HY-P10586A

Macrophage-activating lipopeptide 2 TFA	Activator	98.60%
Macrophage-activating lipopeptide 2 TFA is an agonist of Toll like receptors TLR-2/TLR-6. Macrophage-activating lipopeptide-2 enhances endothelial nitric oxide synthase (eNOS) phosphorylation and endothelial cell release of NO, thereby improving vasodilation. Macrophage-activating lipopeptide-2 enhances endothelial adhesion of white blood cells and improve perfusion recovery and collateral growth in the hind limbs of hypercholesterolemic Apoe deficient mice undergoing experimental femoral artery ligation (FAL).

HY-19891A

Pixatimod free acid	Agonist
Pixatimod free acid (PG545 free acid) is a mimetic of Heparan Sulfate (HY-101916), and exhibits inhibitory activity against heparanase. Pixatimod free acid binds to the S1 receptor binding domain (RBD) of the SARS-CoV-2 virus, that inhibits SARS-CoV-2 isolate strains with EC₅₀ of 2.4-13.8 µg/mL. Pixatimod free acid is an agonist for TLR9 signaling pathway, enhances the activity of dendritic cells (DCs), activates natural killer cells, and exhibits immunomodulatory and anti-tumor activities.

HY-105070A

Eritoran tetrasodium	Antagonist
Eritoran tetrasodium (E5564) is a Toll-like receptor 4 (TLR4) antagonist. Eritoran tetrasodium protects mice against lethal influenza virus infection, such as Ebola virus (EBOV), Marburg virus (MARV). Eritoran tetrasodium decreases the level of granulocytosis, may alleviate the severity of the "cytokine storm". Eritoran tetrasodium inhibits pathogenesis of filovirus infection. Eritoran tetrasodium has anti-inflammatory activity.

HY-139567

Afimetoran	Antagonist	99.37%
Afimetoran (BMS-986256) is an orally active, selective, and highly bioavailable TLR7/8 antagonist. Afimetoran (BMS-986256) can inhibit TLR7/8 activation of the NF-κB pathway and reverse TLR7 mediated resistance to steroid induced apoptosis in plasma cell like dendritic cells (pDCs). Afimetoran (BMS-986256) can be used for research on inflammation and autoimmune diseases (systemic lupus erythematosus).

HY-141537

ABR-238901	Inhibitor	98.71%
ABR-238901 is an orally active and potent S100A8/A9 blocker and inhibits S100A8/A9 interaction with its receptors RAGE (receptor for advanced glycation endproducts) and TLR4 (toll-like receptor 4). ABR-238901 has the potential for myocardial infarction (MI) research.

HY-W021879

DSRM-3716	Inhibitor	99.91%
DSRM-3716 (5-Iodoisoquinoline) is a potent and selective SARM1 NADase inhibitor with an IC₅₀ of 75 nM. DSRM-3716 is selective against other NAD⁺-processing enzymes, receptors, and transporters. DSRM-3716 provides robust axon protection.

HY-N0462

Corilagin		99.96%
Corilagin, a gallotannin, has anti-tumor, anti-inflammatory and hepatoprotective activities. Corilagin inhibits activity of reverse transcriptase of RNA tumor viruses. Corilagin also inhibits the growth of Staphylococcus aureus with a MIC of 25 μg/mL. Corilagin shows anti-tumor activity on hepatocellular carcinoma and ovarian cancer model. Corilagin shows low toxicity to normal cells and tissues.

HY-W250113

Zymosan A	Agonist
Zymosan A (Zymosan A from Saccharomyces cerevisiae) is a TLR2 agonist, that targeting TLRs can prevent and suppress IR-induced intestinal injury. Zymosan A exhibits a significant radioprotective effect, and protects IR-induced intestinal injury in mice. Zymosan A promotes the regeneration of intestinal stem cells (ISCs), after IR injury.

HY-147295

Odetiglucan	Agonist
Odetiglucan is a novel β-glucan that is a potent immunostimulant and a Dectin-1 (CLEC7A) agonist. Odetiglucan activates innate immune effector cells and triggers a coordinated anti-cancer immune response.

HY-150741C

ODN 2216 sodium	Activator
ODN 2216 sodium is a human-specific TLR9 (toll-like receptor 9) ligand or agonist. ODN 2216 sodium induces high amounts of IFN-α and IFN-β. ODN 2216 sodium induces IFN-α by pDC (plasmacytoid DC) and IL-12 (p40) production by DC (dendritic cells). ODN 2216 sodium stimulates IFN-γ production in peripheral blood mononuclear cells (PBMC), which is indirect and mediated by IFN-α/β. ODN 2216 sodium can activate NK cells and promote IFN-γ production of TCR-triggered CD4⁺ T cells.

HY-116961

TH1020	Antagonist	99.81%
TH1020 is a potent and selective toll-like receptor 5 (TLR5)/flagellin complex antagonist with an IC₅₀ of 0.85 μM. TH1020 inhbits flagellin-induced TLR5 signaling. TH1020 is inactive against TLR2, TLR3, TLR4, TLR7 and TLR8.

HY-P2565

Pepinh-TRIF TFA	Inhibitor	99.40%
Pepinh-TRIF (TFA) is a 30 aa peptide that blocks TIR-domain-containing adapter-inducing interferon-β (TRIF) signaling by interfering with TLR-TRIF interaction.

HY-15601

Vesatolimod	Agonist	99.90%
Vesatolimod (GS-9620) is a potent, selective and orally active agonist of Toll-Like Receptor (TLR7) with an EC₅₀ of 291 nM.

HY-107202A

Poly (I:C):Kanamycin (1:1)
Poly (I:C):Kanamycin (1:1) is a mixture of poly (I:C) and kanamycin. Poly(I:C) is a synthetic double-stranded RNA (dsRNA), which is a Toll-like receptor 3 (TLR3) agonist. Kanamycin is positively charged (poly-NH3) and can thus neutralize the negative charge of Poly I:C and thereby stabilized the molecule.

HY-150724C

ODN 1018 sodium	Agonist
ODN 1018 sodium, an oligodeoxynucleotide, is a TLR-9 agonist. ODN 1018 sodium is also a synthetic immunostimulatory sequence that can be used as vaccine adjuvant. Sequence: 5′-TGACTGTGAACGTTCGAGATGA-3′.

Name
Email *

	Sorry, but the email address you supplied was invalid.